ALKEM LABORATORIES share price has zoomed 3% and is presently trading at Rs 5,706.8.
Meanwhile, the BSE HEALTHCARE index is at 41,023.2 (up 0.5%).
Among the top gainers in the BSE HEALTHCARE index today are ERIS LIFESCIENCES (up 3.4%) and Lupin (up 3.2%).
CAPLIN POINT (down 4.3%) and Abbott India (down 3.4%) are among the top losers today.
Over the last one year, ALKEM LABORATORIES has moved up from Rs 4,132.9 to Rs 5,706.8, registering a gain of Rs 1,573.9 (up 38.1%).
On the other hand, the BSE HEALTHCARE index has moved up from 28,300.0 to 41,023.2, registering a gain of 45.0% during the last 12 months.
The top gainers among the BSE HEALTHCARE index stocks during this same period were Jubilant Pharmova (up 114.5%), GSK Pharma (up 106.9%) and GRANULES INDIA (up 104.8%).
Must See: These Segments are Witnessing Incredible Growth with Modi's Push
The BSE Sensex is at 78,995.9 (down 0.6%).
The top losers among the BSE Sensex today are Infosys (down 3.0%) and Power Grid Corp. (down 3.0%). The most traded stocks in the BSE Sensex are Tata Steel and Tata Motors.
In the meantime, NSE Nifty is at 24,154.6 (down 0.6%). LTIMINDTREE and Grasim Industries are among the top losers in NSE NIFTY.
Over the last 12 months, the BSE Sensex has moved up from 65,953.5 to 78,995.9, registering a gain of 13,042.4 points (up 19.8%).
ALKEM LABORATORIES net profit grew 349.9% YoY to Rs 3,045 million for the quarter ended March 2024, compared to a profit of Rs 677 million a year ago. Net sales rose 1.1% to Rs 29,358 million during the period as against Rs 29,026 million in January-March 2023.
For the year ended March 2024, ALKEM LABORATORIES reported 79.9% increase in net profit to Rs 18,115 million compared to net profit of Rs 10,068 million during FY23. Revenue of the company grew 9.2% to Rs 126,676 million during FY24.
The current Price to earnings ratio of ALKEM LABORATORIES, based on rolling 12 month earnings, stands at 37.7.
Equitymaster requests your view! Post a comment on "ALKEM LABORATORIES Gains 3%; BSE HEALTHCARE Index Up 0.5%". Click here!
Comments are moderated by Equitymaster, in accordance with the Terms of Use, and may not appear
on this article until they have been reviewed and deemed appropriate for posting.
In the meantime, you may want to share this article with your friends!